[Form 4] BECTON DICKINSON & CO Insider Trading Activity

Rhea-AI Filing Summary

Michael Feld, EVP & President, Life Sciences at Becton Dickinson & Co (BDX), reported a sale of 58 shares of common stock at $181.03 per share on 09/26/2025, leaving him with 8,302 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 2, 2024.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating preplanned selling
• Remaining beneficial ownership disclosed: 8,302 shares, providing transparency

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine, small insider sale under a pre-established Rule 10b5-1 plan; immaterial to company valuation.

The transaction is a disposal of 58 shares at $181.03 executed under a 10b5-1 plan, which typically indicates preplanned, non-discretionary selling by the insider. The remaining beneficial ownership of 8,302 shares is disclosed, and the size of the sale is negligible relative to typical public-company float, so there is no material impact on BDX's capitalization or immediate investor valuation metrics.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure consistent with good governance; sale follows documented 10b5-1 plan.

The form properly identifies the reporting person and relationship to the issuer and specifies that the transaction occurred pursuant to a Rule 10b5-1 plan adopted August 2, 2024. Use of an established trading plan reduces concerns about opportunistic insider trading and aligns with standard governance practices for executive stock disposals. No other governance issues are evident from this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Feld Michael

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President, Life Sciences

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/26/2025		S		58	D	$181.03	8,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2024.

	Donna Kalazdy, by power of attorney from Michael Feld	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael Feld (BDX) report on this Form 4?

He reported the sale of 58 shares of BDX common stock at $181.03 per share, leaving 8,302 shares beneficially owned.

Was the sale by the BDX executive part of a pre-planned trading arrangement?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024.

What is Michael Feld's role at Becton Dickinson?

The form identifies him as an Executive Vice President & President, Life Sciences of Becton Dickinson & Co.

How many shares does Michael Feld own after the reported transaction?

He beneficially owns 8,302 shares following the reported sale.

What was the transaction date for the reported sale on the Form 4?

The transaction date listed is 09/26/2025.